ferric carboxymaltose

effective for treatment of postpartum anemia

Also Known As:

Ferinject; VIT 45; VIT-45; injectafer; iron carboxymaltose; iron dextri-maltose; polynuclear iron (III)-hydroxide 4(R)-(poly-(1->4)-o-alpha-D-glucopyranosyl)-oxy-2(R),3(S),5(R), 6-tetrahydroxy-hexanoate

Networked: 491 relevant articles (72 outcomes, 157 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Inorganic Chemicals: 9
- Iron Compounds: 87
  - Ferric Compounds: 6
    - ferric carboxymaltose: 491
Carbohydrates: 22023
- Polysaccharides: 15383
  - Oligosaccharides: 3566
    - Disaccharides: 990
      - Maltose: 285
        ferric carboxymaltose: 491
  - Glucans: 1624
    - Maltose: 285
      - ferric carboxymaltose: 491
- Sugars: 11126
  - Disaccharides: 990
    - Maltose: 285
      - ferric carboxymaltose: 491

Experts

1.	Ponikowski, Piotr: 20 articles (01/2022 - 11/2009)
2.	Anker, Stefan D: 19 articles (01/2022 - 11/2009)
3.	Macdougall, Iain C: 14 articles (12/2018 - 01/2013)
4.	Comin-Colet, Josep: 12 articles (01/2022 - 01/2013)
5.	Filippatos, Gerasimos: 12 articles (06/2021 - 11/2009)
6.	Mori, Claudio: 12 articles (01/2019 - 11/2009)
7.	Zoller, Heinz: 10 articles (01/2022 - 01/2016)
8.	Metra, Marco: 9 articles (01/2022 - 10/2017)
9.	Stein, Jürgen: 9 articles (01/2022 - 09/2011)
10.	Wolf, Myles: 9 articles (01/2022 - 07/2010)

Related Diseases

1.	Iron Deficiencies 07/28/2023 - "Administration of ferric carboxymaltose has proved beneficial in studies on iron deficiency correction in cardiological and cardio-surgical patients. " 01/01/2014 - "Overall, as part of this non-interventional study for everyday routine in a gynaecological practice, a rapid improvement in symptoms accompanied by the rectification of iron deficiency and anaemia was shown with low occurrences of mild undesirable events, and therefore the data obtained from controlled clinical studies on the effectiveness and tolerance of intravenous ferric carboxymaltose could be confirmed. " 01/01/2022 - "Clinical studies have shown that iron carboxymaltose (ICM) is an appropriate, effective, and well-tolerated treatment option for clinical situations associated with iron deficiency (ID). " 09/08/2017 - "Intravenous ferric carboxymaltose was safe and effective in pregnent women with iron deficiency anaemia." 03/25/2014 - "Our prospective data is consistent with existing observational reports of the safe and effective use of ferric carboxymaltose in the treatment of iron deficiency anaemia in pregnancy."
2.	Heart Failure 12/01/2014 - "Recently published work (multicentric randomized controlled double-blinde trial) CONFIRM HF have proved that administration of ferric carboxymaltose in heart failure patients have improved their functional ability, NYHA stratification and quality of life. " 11/28/2022 - "Effect of Ferric Carboxymaltose Supplementation in Patients with Heart Failure with Preserved Ejection Fraction: Role of Attenuated Oxidative Stress and Improved Endothelial Function." 01/01/2023 - "Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials." 10/19/2023 - "Men with heart failure with reduced ejection fraction (HFrEF) and ID were randomised in 1:1 ratio to either intravenous ferric carboxymaltose (IV FCM) or placebo. " 09/14/2023 - "Death by month 12 occurred in 131 patients (8.6%) in the ferric carboxymaltose group and 158 (10.3%) in the placebo group; a total of 297 and 332 hospitalizations for heart failure, respectively, occurred by month 12; and the mean (±SD) change from baseline to 6 months in the 6-minute walk distance was 8±60 and 4±59 m, respectively (Wilcoxon-Mann-Whitney P = 0.02; unmatched win ratio, 1.10; 99% confidence interval, 0.99 to 1.23). "
3.	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 10/07/2021 - "Ferric carboxymaltose (FCM) is highly effective in supplementing iron-deficiency anemia and frequently used. " 01/01/2018 - "Ferric carboxymaltose was found to be an effective and well tolerated treatment for iron deficiency anemia in patients with IBD. " 08/01/2023 - "The purpose of this study was to evaluate the safety and efficacy of ferric carboxymaltose (FCM) in reducing the need for perioperative transfusion in iron deficiency anemia patients scheduled for PD. " 01/01/2019 - "Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study." 01/01/2012 - "Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials."
4.	Anemia 01/01/2021 - "Correction of anemia with intravenous ferric carboxymaltose in the third trimester does not significantly change neonatal outcomes but it is effective in reducing maternal morbidity." 03/01/2019 - "Several clinical studies have shown that intravenous iron carboxymaltose supplementation can improve anemia, NYHA class, quality of life and exercise capacity of HFrEF patients. " 10/27/2023 - "ferric carboxymaltose (CF) is an intravenous preparation that helps the rapid correction of anemia with a lower risk of adverse reactions. " 11/09/2022 - "Intravenous ferric carboxymaltose (IV-FCM) can effectively correct perioperative anemia in patients undergoing major surgeries. " 07/01/2021 - "Single Dose of Intravenous Ferric Carboxymaltose Prevents Anemia for 6 Months among Moderately or Severely Anemic Postpartum Women: A Case Study from India."
5.	Chronic Renal Insufficiency 07/01/2015 - "The safety and efficacy of high dose ferric carboxymaltose in patients with chronic kidney disease: A single center study." 01/01/2017 - "Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial." 03/01/2017 - "Ferric carboxymaltose (FCM) can induce hypophosphataemia in the general population and patients with chronic kidney disease (CKD). " 09/01/2015 - "[Clinical experience with ferric carboxymaltose in non-dialysis chronic kidney disease]." 06/01/2014 - "Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients."

Related Drugs and Biologics

1.	Iron
2.	ferric carboxymaltose
3.	Saccharated Ferric Oxide (Venofer)
4.	Hemoglobins (Hemoglobin)
5.	ferrous sulfate
6.	Ferrosoferric Oxide (Magnetite)
7.	Dextrans (Dextran)
8.	Phosphates (Orthophosphate)
9.	Hematinics
10.	Fibroblast Growth Factor-23

Related Therapies and Procedures

1.	Therapeutics
2.	Gastrectomy
3.	Renal Dialysis (Hemodialysis)
4.	Injections
5.	Pancreaticoduodenectomy